Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -20.19% lower on its value in year-to-date trading and has touched a low of $23.95 and a high of $52.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $26.71 in the last trading session, with the day’s gains setting it 1.19%.
Currently trading at $27.90, the stock is -7.54% and -11.29% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.01 million and changing 4.46% at the moment leaves the stock -27.76% off its SMA200. IONS registered -35.03% loss for a year compared to 6-month loss of -26.69%. The firm has a 50-day simple moving average (SMA 50) of $31.4502 and a 200-day simple moving average (SMA200) of $38.6222.
The stock witnessed a -15.20% gain in the last 1 month and extending the period to 3 months gives it a -16.62%, and is 2.99% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.07% over the week and 5.78% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 1069 employees, a market worth around $4.44B and $705.56M in sales. Profit margin for the company is -64.28%. Distance from 52-week low is 16.49% and -46.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.87%).
with sales reaching $143.93M over the same period.The EPS is expected to shrink by -25.51% this year, but quarterly earnings will post -2.52% year-over-year. Quarterly sales are estimated to grow 20.95% in year-over-year returns.
Ionis Pharmaceuticals Inc (IONS) Top Institutional Holders
501.0 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 112.00% of the company’s shares. The shares outstanding are 157.91M, and float is at 154.59M with Short Float at 8.63%. Institutions hold 111.06% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $1.04 billion. The investor’s holdings represent 15.0008% of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6598% and valued at over $602.41 million, while BLACKROCK INC. holds 7.0712 of the shares totaling 10.32 million with a market value of $491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by Monia Brett P, the company’s Chief Executive Officer. SEC filings show that Monia Brett P sold 140 shares of the company’s common stock on Mar 11 ’25 at a price of $32.32 per share for a total of $4525.0. Following the sale, the insider now owns 0.18 million shares.
Still, SEC filings show that on Feb 20 ’25, O’NEIL PATRICK R. (EVP CLO & General Counsel) disposed off 1,207 shares at an average price of $32.35 for $39046.0. The insider now directly holds 56,245 shares of Ionis Pharmaceuticals Inc (IONS).
